Discovery of Pteridine-7(8 H )-one Derivatives as Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK).
Dou DouYanyan DiaoWenjie ShaRongrong SuLinjiang TongWenjie LiLimin LengLijuan XieZhixiao YuHaoming SongZihao ShenLili ZhuZhenjiang ZhaoHua XieZhuo ChenHonglin LiYufang XuPublished in: Journal of medicinal chemistry (2022)
Bruton's tyrosine kinase (BTK) is an attractive therapeutic target in the treatment of cancer, inflammation, and autoimmune diseases. Covalent and noncovalent BTK inhibitors have been developed, among which covalent BTK inhibitors have shown great clinical efficacy. However, some of them could produce adverse effects, such as diarrhea, rash, and platelet dysfunction, which are associated with the off-target inhibition of ITK and EGFR. In this study, we disclosed a series of pteridine-7(8 H )-one derivatives as potent and selective covalent BTK inhibitors, which were optimized from 3z , an EGFR inhibitor previously reported by our group. Among them, compound 24a exhibited great BTK inhibition activity (IC 50 = 4.0 nM) and high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels (ITK >227-fold, EGFR 27-fold). In U-937 xenograft models, 24a significantly inhibited tumor growth (TGI = 57.85%) at a 50 mg/kg dosage. Accordingly, 24a is a new BTK inhibitor worthy of further development.